Blinatumomab for treating pediatric B-lineage acute lymphoblastic leukemia: A retrospective real-world study.

ABSTRACT:

Objectives

Blinatumomab was shown to be safe and effective for consolidation therapy in B-cell acute lymphoblastic leukemia (B-ALL). This study aimed to investigate the effectiveness and safety of blinatumomab in pediatric B-ALL patients in a real-world setting.

Methods

This was a retrospective, observational study that included patients who initiated blinatumomab treatment between October 1, 2020 and June 20, 2022. Patients with B-ALL diagnosis, age below 18 years, and at least one blinatumomab treatment cycle were included. Treatment-related toxicities were assessed.

Result

Totally 23 pediatric patients were included in this study, with a median age of 6 years (range, 2 to 11 years). Blinatumomab therapy was applied for MRD-positive (disease ≥0.01%, n = 3) or

SUBMITTER: Wu Y 

PROVIDER: S-EPMC9638881 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature